(Q34335250)

1 August 2017

1 reference

title

A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America (English)

1 reference

invasive fungal infections

1 August 2017

main subject

1 reference

Kontoyiannis DP

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

21

1 reference

1 August 2017

issue

8 Pt 2

1 reference

1 August 2017

page(s)

175S-187S

1 reference

Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug Administration

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guideline for the treatment of coccidioidomycosis. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Problems and controversies in the management of hematogenous candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Is antifungal susceptibility testing useful in guiding fluconazole therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Etiologic organisms as independent predictors of death and morbidity associated with bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

A pilot study of the management of uncomplicated candidemia with a standardized protocol of amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Candida krusei fungemia. An escalating serious infection in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Importance of Candida species other than C. albicans as pathogens in oncology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever — preliminary observations from a pilot, exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Azole resistance in Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Antifungal susceptibility testing: technical advances and potential clinical applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

The role of the gastrointestinal tract in hematogenous candidiasis: from the laboratory to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Role of catheter colonization and infrequent hematogenous seeding in catheter-related infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Candida sepsis in surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Editorial response: choosing amphotericin B formulations-between a rock and a hard place.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Use of macrophage colony-stimulating factor in the treatment of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Fungal infections in cancer patients: an international autopsy survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Therapeutic outcome in invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Treatment strategies for Aspergillus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Acquired itraconazole resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Early diagnosis of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

The past, present and future of antimycotic combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Problems of antifungal in vitro testing in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Trends in immunotherapy of fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.12.175S.34506

10.1592/PHCO.21.12.175S.34506

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference